Synthesis and preclinical evaluation of two osimertinib isotopologues labeled with carbon-11 as PET tracers targeting the tyrosine kinase domain of the epidermal growth factor receptor-Reference-Cited by-同舟云学术

Synthesis and preclinical evaluation of two osimertinib isotopologues labeled with carbon-11 as PET tracers targeting the tyrosine kinase domain of the epidermal growth factor receptor

Published:2023-05 Issue: Volume:120-121 Page:108349
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Högnäsbacka Antonia,Poot Alex J.,Kooijman Esther,Schuit Robert C.,Schreurs Maxime,Verlaan Mariska,van den Hoek Johan,Heideman Daniëlle A.M.,Beaino Wissam,van Dongen Guus A.M.S.,Vugts Danielle J.,Windhorst Albert D.

Funder

Horizon 2020

Horizon 2020 Marie Skłodowska-Curie Actions

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Molecular Medicine

Reference32 articles.

1. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII);Midha;Am J Cancer Res,2015

2. Biological and clinical implications of EGFR mutations in lung cancer;Mitsudomi;Int J Clin Oncol,2006

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci,2004

5. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanotechnology boosts the efficiency of tumor diagnosis and therapy;Frontiers in Bioengineering and Biotechnology;2023-07-28